7 documents found, page 1 of 1
Reuma.pt contribution to the knowledge of immune-mediated systemic rheumatic di...
Santos, Maria José; Canhão, Helena; Mourão, A. F.; Oliveira Ramos, F.; Ponte, C.; Duarte, C.; Barcelos, A.; Martins, F.; Melo Gomes, J. A.Patient registries are key instruments aimed at a better understanding of the natural history of diseases, at assessing the effectiveness of therapeutic interventions, as well as identifying rare events or outcomes that are not captured in clinical trials. However, the potential of registries goes far beyond these aspects. For example, registries promote the standardization of clinical practice, can also provid...
The Portuguese Society of Rheumatology position paper on the use of biosimilars...
Araújo, Filipe C.; Sepriano, Alexandre; Teixeira, F.; Jesus, D.; Rocha, T. M.; Martins, Paula Andreia; Tenazinha, C.; Cordeiro, A.; Mourão, A. F.Biosimilars are new and more affordable similar versions of previously approved reference biological drugs. Following the approval of the first monoclonal antibody biosimilar in 2013, the Portuguese Society of Rheumatology issued a position paper on the use of biosimilars in rheumatic conditions covering efficacy, safety, extrapolation, interchangeability, substitution and pharmacovigilance. However, as this is...
Portuguese recommendations for the use of biological therapies in patients with...
Duarte, Cátia; Sousa-Neves, J.; Águeda, A.; Ribeiro, P.; Daniel, A.; Eugénio, G.; Silvério Serra, Sofia; Araújo, F.; Barcelos, A.; Filipe, B.Objective: To update the recommendations for the treatment of rheumatoid arthritis (RA) with biological therapies, endorsed by the Portuguese Society of Rheu -matology (SPR). Methods: These treatment recommendations were formulated by Portuguese rheumatologists based on litera -ture evidence and consensus opinion. At a national meeting the 11 recommendations were discussed and updated. The document resulting fr...
Portuguese recommendations for the use of methotrexate in rheumatic diseases - ...
Duarte, Ana Catarina; Santos-Faria, D.; Gonçalves, M. J.; Sepriano, Alexandre; Mourão, A. F.; Duarte, C.; Neves, J. S.; Águeda, A. F.; Ribeiro, P. A.Background: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying antirheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents. Objectives: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic disea...
Portuguese recommendations for the prevention, diagnosis and management of prim...
Maria Rodrigues, Ana; Canhão, Helena; Marques, A.; Ambrosio, C.; Borges, J.; S. Coelho, Pedro; Costa, L.; Fernandes, S.; Goncalves, I; Goncalves, M. J.
Reuma.pt contribution to the knowledge of immune-mediated systemic rheumatic di...
Santos, Maria José; Canhão, Helena; Mourão, A. F.; Ramos, F. O.; Ponte, C.; Duarte, C.; Barcelos, A.; Martins, F.; Melo Gomes, J. A.Patient registries are key instruments aimed at a better understanding of the natural history of diseases, at assessing the effectiveness of therapeutic interventions, as well as identifying rare events or outcomes that are not captured in clinical trials. However, the potential of registries goes far beyond these aspects. For example, registries promote the standardization of clinical practice, can also provid...
The Portuguese Society of Rheumatology position paper on the use of biosimilars...
Araújo, F.C.; Sepriano, Alexandre; Teixeira, F.; Jesus, D.; Rocha, T.M.; Martins, P.; Tenazinha, C.; Cordeiro, A.; Mourão, A.F.; Silva, C.; Vaz, C.Biosimilars are new and more affordable similar versions of previously approved reference biological drugs. Following the approval of the first monoclonal antibody biosimilar in 2013, the Portuguese Society of Rheumatology issued a position paper on the use of biosimilars in rheumatic conditions covering efficacy, safety, extrapolation, interchangeability, substitution and pharmacovigilance. However, as this is...